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lncRNAs in Hallmarks of Cancer 
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Jéssica Barazetti, Daniela Gradia and Jaqueline Oliveira
Abstract
Long noncoding RNAs (lncRNAs) are transcripts longer than 200 nucleotides 
in length that, in general, do not appear to have protein-coding potential. lncRNAs 
act in gene regulation involved with several biological processes. Furthermore, 
lncRNAs have been associated with a significant number of cancers, suggesting a 
potential role in tumorigenesis and progression. For example, HOTAIR regulates 
proliferation processes and other lncRNAs like highly upregulated in liver cancer 
(HULC), H19, PTENP1, HEIH, and antisense noncoding RNA in the INK4 locus 
(ANRIL). Other lncRNAs as AFAP1-AS1 and lincRNA-p21 can interact with BCL-2 
and TP53, acting in apoptosis. Moreover, NORAD plays a vital role in genomic 
stability. Additionally, due to deregulated expression and high tissue specificity 
level, lncRNAs exhibit great potential as prognostic markers. In this chapter, we 
review the most highlighted lncRNAs acting in hallmarks of cancer and clinical 
application.
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1. Introduction
The landscape of human transcriptome is more complicated than was imagined. 
In the last decade, the technology of RNA sequencing reveals more than 100,000 
different RNA molecules produced by mammalian organisms [1, 2], most of them, 
without protein-coding potential, named as noncoding RNAs (ncRNAs). These 
molecules called the attention for their multiple roles in cell physiology. NcRNAs 
are classified, by the size, as small (microRNAs 22~25 bp) or long, with more than 
200 nucleotides [3]. Previously, it was considered that lncRNAs were “dark matter” 
or “transcriptional noise” of the human transcriptome, with no biological func-
tions. Recently, lncRNAs were found in all the branches of the tree of life, and their 
amount and diversity are more correlated with organismal complexity than protein-
coding genes [4].
The majority of lncRNAs is transcribed by RNA polymerase II, capped and poly-
adenylated with some lncRNAs being also spliced. They are described as noncoding 
RNAs. New studies have shown functional micropeptides derived from some of the 
lncRNAs [5]. Until now, 16,000 lncRNAs were identified in the human genome with 
approximately 30,000 distinct lncRNA transcripts according to the Encyclopedia of 
DNA Elements (ENCODE) Project Consortium (GENCODE release 30). This num-
ber continues to increase, mainly through sensitive RNA sequencing and advanced 
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bioinformatics pipelines. lncRNAs have a lower expression level than other RNAs, 
and they show specific expression in tissues [6, 7], cell types, and subcellular com-
partments [8]. lncRNAs are classified according to their relative position to protein-
coding genes in a sense, antisense, bidirectional, intronic, and intergenic [9]. Also, 
lncRNAs can be regulated by well-established transcription factors and associated 
with epigenetic signatures that modify chromatin states, making the lncRNA loci 
more accessible in the cell [10].
The current knowledge about lncRNAs is essential to understand cell biology, 
especially in cancer cells. Cancer is a complex disease characterized by extreme 
genetic and epigenetic changes that can fundamentally alter cell homeostasis to 
promote uncontrolled cell growth. Emerging evidence suggests that lncRNAs are 
involved with cancer-associated phenotypes like resisting cell death, invasion, pro-
liferation, gene deregulation, and genomic instability and evade growth suppressors 
[11]. lncRNAs also interact with transcriptional regulation of tumor suppressors 
or oncogenes [12, 13]. One example is lincRNA-p21 that acts as a repressor in 
p53-dependent transcriptional responses [12]. Alternatively, HOTAIR can increase 
metastasis in primary breast tumors and hepatocellular carcinomas [14].
lncRNAs can participate in gene regulation at transcriptional and posttran-
scriptional levels [15]. For example, related to epigenetic mechanisms, lncRNAs 
can recruit methyltransferases [16] and polycomb complex [17] to prevent DNA 
accessibility through histone modification. lncRNAs are also involved in several 
posttranscriptional processes, such as splicing and nuclear export, mRNAs localiza-
tion and stability, and in protein translation process [18–22].
lncRNAs can serve as a molecular scaffold, enhancing the interactions between 
protein-protein, protein-RNA, and protein-DNA, by base complementarity or 
interaction by secondary structures [23]. Alternatively, lncRNAs can function as a 
decoy when they titrate transcription molecules and other proteins away from the 
target [24]. Additionally, lncRNAs can work as binding platforms regulating miR-
NAs competing with mRNAs for miRNA response elements, known as competitive 
endogenous [25].
The development of several discoveries about the role of lncRNAs, especially 
in cancer, highlighted the importance of gene regulation in cellular functions. The 
evidence that we show here supports the idea that lncRNAs have an essential role in 
tumorigenesis and are associated with several cellular processes. Here, we review 
the current knowledge about lncRNAs in hallmarks of cancer and their potential for 
clinical application.
2. lncRNAs act in hallmarks of cancer
The transformation of a regular cell into cancer involves several processes, 
including molecular and environmental alterations [26]. The healthy cells must 
acquire different abilities to change the cell physiology and dictate malignant 
growth. The hallmarks of cancer comprise the biological capabilities acquired dur-
ing the multistep development of human tumors. These changes include sustaining 
proliferative signaling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, and activating invasion/metastasis 
[27]. Additionally, genomic instability, inflammation, reprogramming of energy 
metabolism, and evading immune destruction were also included [28]. There are 
many lncRNAs well described associated with cancer [29], and, herein, we high-
lighted some lncRNAs with strong evidence for cancer process association and with 
molecular details, for exemple (Figure 1). The influence of those long noncoding 
RNAs in hallmarks of cancer is due to the regulation of different pathways.
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lncRNAs have virtual association in all the hallmarks of cancer, some of them 
linked with more than one hallmark. For example, the expression of ANRIL, 
growth arrest-specific transcript 5 (GAS5), urothelial cancer-associated 1 (UCA1), 
and HULC regulates the resistance to cell death. Also, ANRIL, HULC, and H19 
are associated with the evasion of growth suppressors, GAS5, and H19, sustaining 
cell proliferation. UCA1 and H19 are also associated with invasion and metastasis. 
Moreover, UCA1 is associated with metabolism reprogramming and GAS5 with an 
inflammatory process.
In more detail, ANRIL may inhibit apoptosis by silencing KFL2 and p21 genes, 
involved in cell proliferation. Moreover, regulating MET and MMP3 proteins that 
facilitate cell migration and invasion [30–34].
The lncRNA GAS5 can sustain proliferation by regulating glucocorticoid recep-
tors (GR), with strong influences in cell growth and repression of anti-apoptosis 
genes. lncRNA binds to the DNA-binding domain of GR, competing with glucocor-
ticoid response element [35].
lncRNA is also observed in cell cycle regulation, whereas it arrests cells in the 
G0/G1 phase. In stomach cancer, GAS5 binds to YBX1 to regulate p21 expression, 
enhancing G1 arrest. In bladder cancer, GAS5 associates with CDK6 and reduces 
both CDK6 mRNA and protein levels, resulting in the inhibition of cell prolifera-
tion. Besides, GAS5 acts in the immune response by NF-κB and ERK1/2 pathways. 
The knockdown of GAS5 increases expression and secretion of interleukin-10 
(IL-10) and vascular endothelial growth factor (VEGF-A), the essential cytokines 
involved in inflammation [36].
Due to its oncogenic regulatory potential, the lncRNA UCA1 regulates the 
proliferation and migration targeting the transcription factor KLF832 in pan-
creatic cancer. UCA1 also promotes invasion and metastasis through activation 
of MMP14, FGFR1/ERK, and ZEB1/2-FSCN1 [37–40]. In hypoxic conditions, 
HIF-1α effectively activates UCA1 transcription by binding in the UCA1 pro-
moter, inducing proliferation, migration, invasion, and apoptosis resistance of 
cancer cells [41].
Several pathways regulate the switch of oxidative phosphorylation to aerobic 
glycolysis, such as the PI3K, AMPK, p53, and HIF-1 pathways. These pathways 
Figure 1. 
lncRNAs in hallmarks of cancer.
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are involved in metabolism deregulation associated with the Warburg effect, 
which consists in the special metabolism of glucose in the cytosol even in the 
presence of oxygen [42, 43], and UCA1 acts indirectly in genes involved in this 
process [44, 45].
HULC contributes to malignant phenotypes by, at least, three mechanisms. 
The first is regulating the expression of P18, an auxiliary protein of cell cycle that 
inhibits the tumor suppressors CDK4 and CDK6. Also, hepatitis B virus infection 
activates the HULC promoter and induces cell cycle progression by downregula-
tion of P18 [46]. The other two mechanisms are related to angiogenesis. In breast 
and liver cancer, HULC sequesters miR-107 and regulates the transcription factor 
E2F1/SPHK1 [47, 48]. In glioma, HULC acts through PI3K/Akt/mTOR signaling 
pathway, inducing ESM-1/VEGF-A and affecting vascular permeability and cell 
mobilization [49].
Some lncRNAs have been described more exclusively in only one hallmark, for 
example, telomeric repeat-containing RNA (TERRA) associated with replicative 
immortality. We know that cells have a limited survival rate that can be explained 
by telomere end loss, which generate a waste of genetic conservation, restricting 
the number of mitosis in a tissue. Thus, neoplastic cells can escape this telomere 
process with the help of telomerase. This enzyme can increase the size of telomere 
adding repeats on the edge 3′ in chromosomes [50]. TERRA comprises a heteroge-
neous class of lncRNAs transcribed from telomeric regions [51]. TERRA transcripts 
negatively regulate the activity of telomerase, acting as a tumor suppressor. Besides 
acting as telomere maintenance and genome stability, TERRA is also regulated by 
genes, such as TP53 and RB, highlighting that TERRA transcripts can be crucially 
involved in tumorigenesis [52–54].
Another critical feature of neoplastic cells is in genomic instability, which can be 
related to defects in the DNA repair machinery. Activation of telomerase, following 
by individual DNA variations, activating proto-oncogenes or deactivating tumor 
suppressor genes, conferring a selective advantage on subclones of tumor cells, 
enabling their survival and outgrowth [28].
One lncRNA that is important in this tumor cell feature is NORAD. lncRNA pro-
tects the cells against aneuploidy by binding to PUM1/PUM2 proteins and suppress-
ing their binding to other targets, including those that maintain genomic stability 
[55, 56]. An alternative mechanism to define the relationship among NORAD and 
genomic stability is that a nuclear ribonucleoprotein complex, named NORAD-
activated ribonucleoprotein complex 1 (NARC1), is joined by NORAD, recruiting 
proteins known to act as suppressors of genomic instability, such as topoisomerase I 
(TOP1), ALYREF, and the PRPF19-CDC5L [57].
The implication of lncRNAs in cancer development and progression has been 
proved in the last decade and indicates that those new class of RNAs has a great 
potential as biomarkers on cancer and a future perspective to targeted specific 
therapies.
3. Clinical application for lncRNAs
As we discussed in earlier topics, we have examples of lncRNAs that participate 
in essential processes in tumor development. Many of them have great potential 
as diagnostic/prognostic markers and therapeutic targets. A great example is the 
lncRNA prostate cancer antigen 3 (PCA3), already used as a molecular marker in 
prostate cancer [58, 59]. PCA3 is a prostate-specific lncRNA overexpressed in 95% 
of prostate cancer cases. PCA3 may be detected by in vitro nucleic acid amplification 
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in urine specimens, and the US Food and Drug Administration approved the test in 
2012 [60].
In cases of suspicion of prostate cancer, the PCA3 test is recommended, based 
on prostate-specific antigen (PSA) level and post-digital rectal examination with 
biopsy results. PCA3 has a high expression in prostate cancer without any correla-
tion to prostatic volume and other prostatic diseases. This feature makes a PCA3 an 
attractive biomarker [61], but some recent studies question the use of this isolated 
biomarker and propose that the test should be carried out in association with 
another test, like TMPRSS2:ERG quantification [58].
Although there are few lncRNAs used in medical practice, many are being dis-
covered and tested. For example, a treatment protocol for triple-negative high-risk 
breast cancer predicted by the integrated mRNA-lncRNA signatures is initiated in 
the clinical trials evaluated, to validate the efficacy of lncRNA signature [62].
Also, in clinical trials, there is an early phase study to evaluate the HOTAIR as 
a potential lncRNA biomarker in thyroid cancer. Many lncRNAs have a different 
expression in tumors when compared to healthy tissues and are strongly associ-
ated with clinical parameters, making them a candidate for tumor markers or even 
therapeutic targets [63].
A study found the downregulation of expression of downregulated in liver can-
cer (DILC) in colorectal cancer tissues compared to their adjacent healthy tissues 
and the normal colorectal tissues. The downregulation of DILC was associated with 
aggressive clinical characteristics, including depth of invasion and advanced TNM 
stage, and the lower expression of DILC was associated with more reduced survival 
and disease-free survival. With multivariate analyses, the authors confirmed that 
the expression of DILC was an independent prognostic factor in colorectal cancer 
[64]. Most of lncRNA papers characterize biomarkers that are specific to one type 
of cancer, such as those cited above. However, some lncRNAs are found differen-
tially expressed in several types of cancer compared with healthy tissues, like the 
loc285194 lncRNA [65].
In addition to the association of lncRNAs with stage and prognosis, their 
association with drug resistance is also possible [66]. Several works have tried to 
reallocate the lncRNAs in the mechanism of resistance to the primary drugs used 
in the treatment of cancer. For example, Campos-Parra et al. [67] have identified 
several lncRNAs that participate in resistance mechanisms to several drugs utilized 
in the therapy of breast cancer. Most studies with lncRNAs measure their expression 
in tissues, but it is possible to detect and quantify their presence in other types of 
samples, like whole blood, plasma, urine, gastric acid, and saliva [68].
Within the use of lncRNAs as biomarkers in cancer, these molecules have appli-
cations as therapeutic targets in the development of new treatments and drugs. New 
therapeutic strategies are already focusing on noncoding RNAs, such as silencing 
via small interfering RNA (siRNA), an antisense oligonucleotide (ASO)-based strat-
egies and other molecular inhibitors further modulating lncRNA expression by gene 
editing [69, 70]. An experimental model that aims to modulate lncRNAs in cancer 
cells is the use of siRNAs, which can decrease the amount of a target lncRNA, since 
they are complementary molecules to the sequence of lncRNA, promoting lncRNA 
binding and subsequent degradation. Although this methodology may be func-
tional in many studies, some lncRNAs are not efficiently reduced by siRNA [70]. 
This methodology is efficient for cytoplasmic lncRNAs since the siRNA mechanism 
is located predominantly in the cytoplasm. In this case, siRNA does not silence 
nuclear lncRNAs [11, 71].
Another mechanism used to block lncRNAs activity relies on the ability of 
lncRNAs to bend and create secondary structures and on the ability of protein 
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interactions in lncRNAs. RNAi molecule can compete with the protein for the bind-
ing site; or when it binds to the target lncRNA, it changes the structure of the RNA, 
disrupting the binding site of the protein [72, 73].
For nuclear lncRNAs, an alternative strategy is the use of antisense oligonucle-
otides, which function predominantly in the nucleus [71]. ASOs modulate gene 
expression by inducing ribonuclease H cleavage of the duplex DNA-RNA. A limita-
tion of the ASO and siRNA strategies is the possibility of non-specific targets, as 
well as the inconvenience of incomplete knockdown and transient modulation [74]. 
One method that has shed light on ncRNA-based cancer therapy and solves the 
problem of target specificity is genome editing by clustered regularly interspaced 
short palindromic repeats-associated endonuclease 9 (CRISPR/Cas9). The Cas9 
nuclease can act guided to generate site-specific DNA cleavage in the genome, by an 
optimized equivalent single-guide RNA (sgRNA) [75]. That is, it can delete lncRNA 
genes or introduce RNA-destabilizing elements into their locus.
A limitation to apply CRISPR/Cas9 system to noncoding genes is that tiny indels 
may not necessarily generate a functional loss of a specific noncoding gene and the 
most protocols can perform small point mutations; plus not all lncRNAs CRISPR 
can be applied. Another limitation is that, although it is more specific than other 
systems, this technique may still have off-target effects [76, 77].
Currently, many studies performed lncRNA modulation technologies, both 
in vitro and in vivo. Moreover, while these models may resemble reality, the clinical 
use of modulation technology has a barrier that still needs to be broken: an efficient 
delivery to the target. There are some techniques for delivering lncRNA modula-
tion systems to live cells, based on viral and non-viral methods, but both ways have 
limitations and problems to be solved before the utilization in clinical practice.
The main advantage of viral vectors is their innate ability to efficiently transfer 
the genetic material into the cell and the possibility of infecting specific cells. 
However, this technique also has a significant disadvantage, which is relatively high 
immunogenicity and toxicity. The possibility of generating an immune response is 
the main challenge for the use of this tool [78, 79].
Non-viral vectors are becoming recognized as an alternative to the immuno-
genicity of viral vectors, although their transfection capabilities usually do not 
reach such levels. Besides its main strengths are the low capacity to generate an 
immune response and the relatively easy and inexpensive synthesis with large-
scale production and safety, which make them very attractive delivery systems 
for in vivo application. However, the target specification still needs to be better 
developed [79].
In order to choose the best delivery system, it is necessary to consider the type 
of cell/tissue, since some tissues are more accessible than others. When the target of 
therapy is a difficult-to-access tissue, some strategies may improve delivery efficien-
cies, such as binding to specific targeting elements like antibodies, carbohydrates, 
and synthetic peptides. These molecules also have their advantages and limitations; 
for example, although antibodies have a high recognition specificity and interaction 
with different receptors on target cells, they may be immunogenic and chemically 
unstable. Peptides and carbohydrates, on the other hand, demonstrate low immu-
nogenicity, but the binding affinity to the target is lower [79, 80].
All the techniques cited in this topic have their limitations. Although in vitro 
studies present satisfactory results that have the potential to use in clinical aspects. 
However, these techniques require better improvements, especially in the delivery 
of drugs in specific targets. Despite this, our knowledge of lncRNAs linked with 
clinical applications creates hope for the development of better biomarkers and 
therapeutic targets. In Table 1, we list the main lncRNAs that have excellent poten-
tial for biomarker and therapeutic target.
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Cancer
lncRNAs Head/
neck
Gastric Lung Breast Pancreas Liver Colon Uterine Ovarian Osteosarcoma Prostate Bladder Renal SNC Leukemia Refs.
AFAP1-AS1 x x x x x x x x x x [81]
ANRIL x x x x x x x x x x x x x x x [82, 
83]
CCAT1/
CCAT2
x x x x x x x x x x x x x x x [84]
CRNDE x x x x x x x x x x x x [85]
DANCR x x x x x x x x [85]
GAS5 x x x x x x x x x x x x x x [86]
H19 x x x x x x x x x x x x x x x [87]
HOTAIR x x x x x x x x x x x x x x X [88]
HULC x x x x x x x x x x x x x [89]
LINC00152 x x x x x x x x x x x [90]
LincRNA- 
p21
x x x x x x [91]
Linc-RoR x x x x x x x x [92]
MALAT1 x x x x x x x x x x x x x x x [93]
MALAT2 x [94]
MEG3 x x x x x x x x x x x x x x x [95]
MIAT x x x x x x x x x [96]
NEAT1 x x x x x x x x x x x x x x [97]
PANDA x x x x x x x x [98]
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Cancer
lncRNAs Head/
neck
Gastric Lung Breast Pancreas Liver Colon Uterine Ovarian Osteosarcoma Prostate Bladder Renal SNC Leukemia Refs.
PCA3 x x [99, 
100]
PCAT-1 x x x x x x x x x x x [101, 
102]
TUG1 x x x x x x x x x x x x x x [103, 
104]
XIST x x x x x x x x x x x x x [105]
Table 1. 
lncRNAs with potential to be used as biomarkers, in several types of cancer.
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4. Conclusion
The vast number of studies describing lncRNAs associated with several tumor 
types and regulating several processes of cancer cells is shown here. The great 
advance in RNA sequencing technology allows us to identify new molecules and 
characterized better lncRNAs. From the discovery of these molecules, in the 
beginning, they appeared to have no important functions; however, today many 
researches in this area propose that more information about these molecules may 
help us understand numerous characters of tumor cells that are still unknown. 
Some lncRNAs are associated with several hallmarks of cancer demonstrating 
the importance of these molecules in the mechanism of disease, like MALAT and 
HOTAIR. Other are already utilized as biomarker in prostate cancer like PCA3. 
Considering the challenges for in vivo experimental designs, lncRNAs continue to 
be promising as biomarkers and potential therapeutic targets.
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